A San Francisco startup backed by OpenAI CEO Sam Altman and his husband Oliver Mulherin is drawing scrutiny for its work on gene-edited human embryos, with ambitions that some critics warn echo the dystopian themes of the 1997 film Gattaca. The company, named Preventive, says it seeks to use gene-editing technology to prevent hereditary genetic diseases from being passed from parents to their children.
While the stated goal is disease prevention, human embryo editing remains illegal in the United States. Preventive has reportedly sought to operate in jurisdictions with less restrictive regulations, prompting concern among scientists and ethicists. Critics have called for a global moratorium on advanced gene-editing in humans, citing unresolved technical and moral questions.
Experts warn that expanding such work could pave the way for designer babies, enabling parents to select traits such as eye color, height, or even intelligence. The potential consequences include a widening societal divide, with genetically enhanced individuals forming an elite class while unmodified humans could face systemic disadvantages, raising fears of a “techno-feudal” future.
The investment highlights the growing intersection of Silicon Valley innovation and ethically fraught biotechnologies, prompting renewed debate about the governance of human genetic modification and the role of private companies in shaping the future of human evolution.
